IKT Inhibikase Therapeutics, Inc.
$1.57▲ +3.29%
Healthcare
Other
After hours
$1.57▲ +0.00%
Oct 27, 4:41 PM ET
Volume 1.19M
Avg Volume (10D) 786.4K
Key Metrics & Fundamentals
Market Cap
$219.07M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.33 - 2.61
% vs 50 MA
-26.07%
% vs 200 MA
-18.99%
RSI-14
30.4
MACD Histogram
-0.0100
Beta (1Y vs SPY)
1.39
Free Cash Flow
-$12.44M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$21.05M
COGS
–
Operating Exp
$21.05M
Operating Income
-$21.05M
EBIT
-$21.05M
Pretax Income
-$19.59M
Net Income
-$19.59M
EPS (Diluted)
-0.11
Price & Volume History
Loading chart…
Recent News
Inhibikase Therapeutics Announces Participation in Upcoming Investor Conferences During November 2026
GlobeNewswire · Oct 27, 2026 8:00 AM ET
Inhibikase Therapeutics Appoints Scott Wasserman to Board of Directors
GlobeNewswire · Oct 20, 2026 4:01 PM ET
Chardan Initiates Inhibikase Therapeutics at Neutral With $1.50 Price Target
MT Newswires · Oct 13, 2026 5:14 AM ET
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Oct 2, 2026 4:01 PM ET
Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity
GlobeNewswire · Aug 11, 2026 4:01 PM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See IKT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.